Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GC012F in High-Risk Newly Diagnosed Multiple Myeloma
NCT04935580Phase 2Unknown
- Sponsor
- Shanghai Changzheng Hospital
- Start
- Jun 2021
- Primary completion
- Jul 2023
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
A Phase 2 trial of GC012 in multiple myeloma (MM), sponsored by Shanghai Changzheng Hospital. Status: unknown.
02
Drugs
GC012
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT04935580.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04935580.